DRREDDY
Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
1,356.10 INR4.10 +0.30%
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY) last traded at 1,356.10 INR, up 0.30% on the day. Over the past year the stock is up 12.77%. Its 52-week range is 1,101.00 to 1,414.90. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open1,352.00
Day range1,347.20 – 1,364.90
52-week range1,101.00 – 1,414.90
Volume917.85 K
Average volume (10 days)2.63 M
Market cap (USD)11.86 B
P/E40.41
EPS (TTM) (USD)0.3496
Dividend yield0.59%
Beta (1 year)0.2084
Revenue (TTM) (USD)3.44 B
Employees27.53 K
Performance
+7.63%1 week
+9.98%1 month
+15.51%3 months
+5.78%6 months
+6.78%Year to date
+12.77%1 year
Technical rating
Buy
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
1,361.65 INR
The average 1-year price target, +0.41% from the last price. See the forecast
Latest headlines
- Weekly Recap: Q2 beat and U.S. intravenous abatacept Dec 2026TradingView · 02 Nov 2026
- Dr. Reddy's Laboratories Ltd Stock 12‑Month Price Target Raised to $14.25, Implies 1% UpsideTradingView · 30 Oct 2026
- Buzzing stocks: TVS Motor, Fortis Healthcare, Dr Reddy’s, Bajaj Electricals, Titagarh, Zaggle, Awfis, HD Fire, KIMS, ShalbyBusiness Line · 29 Oct 2026
- NPPA revises MRP of 543 anti-cancer medicine brands; new prices effective from November 9Asian News International · 28 Oct 2026
- Dr Reddy's Says USFDA Classifies Inspection Outcome As Vai And Inspection Officially ClosedReuters · 28 Oct 2026
- Dr Reddy's stock could rise 10-15% if a major biosimilar gets approved in December: SystematixCNBC TV18 · 27 Oct 2026
- Dr. Reddy's Laboratories Ltd Stock 12‑Month Price Target Raised to $14.01, Implies 6% UpsideTradingView · 26 Oct 2026
- Dr Reddy's Q2 profit falls 36%, plans semaglutide relaunch in NovemberMint · 26 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.